Understanding the stages of Merkel cell carcinoma (MCC) helps you and your physician know how far the cancer has grown or spread. These stages also guide decisions about the treatment options your ...

We unite the leading researchers and cancer specialists of Fred Hutch and UW Medicine so you can take part in Merkel cell carcinoma (MCC) research through clinical trials not available everywhere.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

Merkel cell carcinoma is a rare but fast-growing neuroendocrine cancer that is three to five times more likely than melanoma to be deadly. Response rates to current therapies – surgery, radiation and ...

Please provide your email address to receive an email when new articles are posted on . Merkel cell carcinoma is often diagnosed after metastasis to other organs. However, new findings show those with ...

"Parrotheads" and casual fans of Caribbean living mourned the death of "Margaritaville" singer Jimmy Buffett over the weekend, who died at the age of 76 after a years-long battle with a rare and ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was not significant. HealthDay News — For patients with resected Merkel cell carcinoma (MCC), adjuvant ...

Patients undergoing resection of Merkel cell carcinoma have improved distant metastasis-free survival with adjuvant pembrolizumab — but any benefits for overall survival remain to be seen.

Please provide your email address to receive an email when new articles are posted on . 65.1% and 63.8% of Merkel cell carcinoma cases were attributed to ambient ultraviolet radiation exposure and ...

Comparative of PD-L1 expression on live single circulating tumor cells with PD-L1 in tumor tissue assessed by immunohistochemistry in advanced NSCLC patients. This is an ASCO Meeting Abstract from the ...